MD on NYSE
Pediatrix Medical Group
Logo: pediatrix.com3
Pediatrix Medical Group is an American physician-led national medical group based in Sunrise, founded in 1979.1 Its website says: “Led by physicians and trusted by patients, Pediatrix delivers advanced medical solutions across a variety of practice areas around the country.”3 Its shares trade on NYSE under the symbol MD.1
Price unavailable
Last updated Oct 21, 2026.
Overview
1979Founded1
Compare with Magellan Health, Select Medical or Encompass Health, or pick any stock.
- TickerMD on NYSE1
- IndustryServices-Hospitals1
- HeadquartersSunrise1
- Websitewww.pediatrix.com
- Incorporated inFL4
- Business address1301 Concord Terrace, Sunrise, Fl 333234
- Filer categoryLarge accelerated filer4
See how the biggest companies compare on our leaderboards
Pediatrix is a leading provider of physician services including newborn, maternal-fetal, and other pediatric subspecialty care. Our national network is comprised of affiliated physicians who provide clinical care in 37 states. During 2024, we formalized our practice portfolio management plans, resulting in a decision to exit almost all of our affiliated office-based practices, other than maternal-fetal medicine. As of December 31, 2024, these plans were completed. Additionally, we exited our primary and urgent care service line during 2024 based on a review of the cost and time that would be required to build the platform to scale. At December 31, 2025, our national network comprised approximately 2,295 affiliated physicians, including 1,350 physicians who provide neonatal clinical care, primarily within hospital-based neonatal intensive care units (“NICUs”), to babies born prematurely o…6 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Health Care, Patient Service brought in 85% of the revenue Pediatrix Medical Group broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Health Care, Patient Service | $1.7B | $1.7B | $1.6B |
| Hospitals Contracts | $275.7M | $286.7M | $271.1M |
| Product and Service, Other | $2.6M | $2.6M | $12.2M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Other costs89¢$1.7B
- Income tax3¢$51.0M
- Profit9¢$165.4M
Out of $1.9B in revenue.7
Where each dollar of operating cash went, fiscal 2025
- Share buybacks32¢$86.7M
- Kept or used elsewhere68¢$184.4M
Out of $271.1M of cash from operations.7
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.7
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net revenue | $1.9B | $2.0B | $2.0B |
| Practice salaries and benefits | $1.3B | $1.4B | $1.4B |
| Practice supplies and other operating expenses | $79.3M | $117.7M | $124.8M |
| General and administrative expenses | $240.8M | $238.4M | $227.5M |
| Depreciation and amortization | $21.8M | $32.2M | $36.2M |
| Transformational and restructuring related expenses | $22.3M | $64.3M | $2.2M |
| Goodwill impairment | $150.6M | $148.3M | |
| Long-lived asset impairments | $27.8M | $0 | |
| Loss on disposal of businesses | $0 | $9.7M | $0 |
| Total operating expenses | $1.7B | $2.1B | $2.0B |
| Income (loss) from operations | $208.8M | -$68.7M | $7.3M |
| Investment and other income | $19.0M | $5.8M | $4.3M |
| Net gain on investments in divested businesses | $20.9M | $0 | $0 |
| Interest expense | -$36.0M | -$40.7M | -$42.1M |
| Impairment of strategic investment | $0 | -$20.0M | |
| Equity in earnings of unconsolidated affiliate | $3.6M | $2.3M | $2.1M |
| Total non-operating income (expenses) | $7.6M | -$32.6M | -$55.7M |
| Income (loss) before income taxes | $216.4M | -$101.3M | -$48.4M |
| Income tax (provision) benefit | -$51.0M | $2.3M | -$12.0M |
| Net income (loss) | $165.4M | -$99.1M | -$60.4M |
| Unrealized holding gain on investments, net of tax of $526, $374 and $527 | $1.7M | $1.1M | $1.5M |
| Total comprehensive income (loss) | $167.1M | -$97.9M | -$58.9M |
| Basic | $1.97 | -$1.19 | -$0.73 |
| Diluted | $1.94 | -$1.19 | -$0.73 |
| Basic | 84.1M shares | 83.3M shares | 82.2M shares |
| Diluted | 85.3M shares | 83.3M shares | 82.2M shares |
| Net of Tax | $525.0K | $374.0K | $527.0K |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.7
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $375.2M | $229.9M | |
| Short-term investments | $124.5M | $118.6M | |
| Accounts receivable, net | $229.7M | $260.0M | |
| Prepaid expenses | $12.6M | $13.4M | |
| Income Taxes receivable | $12.6M | $12.6M | |
| Other current assets | $8.9M | $5.1M | |
| Total current assets | $763.5M | $639.6M | |
| Property and equipment, net | $39.2M | $39.2M | |
| Goodwill | $1.3B | $1.2B | $1.4B |
| Intangible assets, net | $16.9M | $11.6M | |
| Operating and finance lease right-of-use assets | $34.3M | $39.3M | |
| Deferred income tax assets | $73.9M | $103.9M | |
| Other assets | $58.2M | $76.6M | |
| Total assets | $2.2B | $2.2B | |
| Accounts payable and accrued expenses | $419.5M | $398.7M | |
| Current portion of debt and finance lease liabilities, net | $26.8M | $20.5M | |
| Current portion of operating lease liabilities | $11.6M | $12.7M | |
| Income taxes payable | $984.0K | $2.2M | |
| Total current liabilities | $458.9M | $434.1M | |
| Long-term debt and finance lease liabilities, net | $570.5M | $597.1M | |
| Long-term operating lease liabilities | $25.7M | $31.9M | |
| Long-term professional liabilities | $238.4M | $257.5M | |
| Deferred income tax liabilities | $57.0M | $34.2M | |
| Other liabilities | $30.3M | $32.9M | |
| Total liabilities | $1.4B | $1.4B | |
| Preferred stock; $.01 par value; 1,000,000 shares authorized; none issued | $0 | $0 | |
| Common stock; $.01 par value; 200,000,000 shares authorized; 82,976,110 and 85,866,000 shares issued and outstanding, respectively | $830.0K | $859.0K | |
| Additional paid-in capital | $947.6M | $1.0B | |
| Accumulated other comprehensive income (loss) | $610.0K | -$1.1M | |
| Retained deficit | -$83.2M | -$248.5M | |
| Total shareholders' equity | $865.9M | $764.9M | |
| Total liabilities and shareholders' equity | $2.2B | $2.2B | |
| Preferred stock, par value | $0.01 | $0.01 | |
| Preferred stock, shares authorized | 1.0M shares | 1.0M shares | |
| Preferred stock, issued | 0 shares | 0 shares | |
| Common stock, par value | $0.01 | $0.01 | |
| Common stock, shares authorized | 200.0M shares | 200.0M shares | |
| Common stock, shares issued | 83.0M shares | 85.9M shares | |
| Common stock, shares outstanding | 83.0M shares | 85.9M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $375.2M | $229.9M | |
| Short-term investments | $124.5M | $118.6M | |
| Accounts receivable, net | $229.7M | $260.0M | |
| Prepaid expenses | $12.6M | $13.4M | |
| Income Taxes receivable | $12.6M | $12.6M | |
| Other current assets | $8.9M | $5.1M | |
| Total current assets | $763.5M | $639.6M | |
| Property and equipment, net | $39.2M | $39.2M | |
| Goodwill | $1.3B | $1.2B | $1.4B |
| Intangible assets, net | $16.9M | $11.6M | |
| Operating and finance lease right-of-use assets | $34.3M | $39.3M | |
| Deferred income tax assets | $73.9M | $103.9M | |
| Other assets | $58.2M | $76.6M | |
| Total assets | $2.2B | $2.2B | |
| Accounts payable and accrued expenses | $419.5M | $398.7M | |
| Current portion of debt and finance lease liabilities, net | $26.8M | $20.5M | |
| Current portion of operating lease liabilities | $11.6M | $12.7M | |
| Income taxes payable | $984.0K | $2.2M | |
| Total current liabilities | $458.9M | $434.1M | |
| Long-term debt and finance lease liabilities, net | $570.5M | $597.1M | |
| Long-term operating lease liabilities | $25.7M | $31.9M | |
| Long-term professional liabilities | $238.4M | $257.5M | |
| Deferred income tax liabilities | $57.0M | $34.2M | |
| Other liabilities | $30.3M | $32.9M | |
| Total liabilities | $1.4B | $1.4B | |
| Preferred stock; $.01 par value; 1,000,000 shares authorized; none issued | $0 | $0 | |
| Common stock; $.01 par value; 200,000,000 shares authorized; 82,976,110 and 85,866,000 shares issued and outstanding, respectively | $830.0K | $859.0K | |
| Additional paid-in capital | $947.6M | $1.0B | |
| Accumulated other comprehensive income (loss) | $610.0K | -$1.1M | |
| Retained deficit | -$83.2M | -$248.5M | |
| Total shareholders' equity | $865.9M | $764.9M | |
| Total liabilities and shareholders' equity | $2.2B | $2.2B | |
| Preferred stock, par value | $0.01 | $0.01 | |
| Preferred stock, shares authorized | 1.0M shares | 1.0M shares | |
| Preferred stock, issued | 0 shares | 0 shares | |
| Common stock, par value | $0.01 | $0.01 | |
| Common stock, shares authorized | 200.0M shares | 200.0M shares | |
| Common stock, shares issued | 83.0M shares | 85.9M shares | |
| Common stock, shares outstanding | 83.0M shares | 85.9M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.7
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net Income (Loss) | $165.4M | -$99.1M | -$60.4M |
| Depreciation and amortization | $21.8M | $32.2M | $36.2M |
| Amortization of premiums, discounts and issuance costs | $935.0K | $954.0K | $1.2M |
| Impairment losses | $0 | $178.4M | $168.3M |
| Loss on disposal of businesses | $0 | $9.7M | $0 |
| Net gain on investments in divested businesses | -$20.9M | $0 | $0 |
| Stock-based compensation expense | $18.0M | $11.9M | $12.3M |
| Deferred income taxes | $52.2M | -$2.1M | $3.2M |
| Other | -$4.6M | -$3.0M | -$3.2M |
| Accounts receivable | $30.6M | $10.3M | $26.3M |
| Prepaid expenses and other current assets | -$2.9M | $3.5M | $514.0K |
| Other long-term assets | $21.8M | $33.7M | $22.9M |
| Accounts payable and accrued expenses | $28.3M | $51.1M | -$11.9M |
| Income taxes (payable) receivable | -$1.2M | -$5.0M | -$21.7M |
| Long-term professional liabilities | -$8.7M | $17.3M | $837.0K |
| Other liabilities | -$26.1M | -$22.7M | -$28.5M |
| Net cash provided by operating activities - continuing operations | $274.7M | $217.2M | $146.1M |
| Net cash used in operating activities - discontinued operations | -$3.6M | -$10.7M | -$8.8M |
| Net cash provided by operating activities | $271.1M | $206.6M | $137.3M |
| Acquisition payments, net of cash acquired | -$23.2M | -$8.2M | -$6.7M |
| Purchases of investments | -$29.9M | -$64.5M | -$31.9M |
| Proceeds from maturities or sales of investments | $26.7M | $52.5M | $22.9M |
| Proceeds from investment in divested business | $30.0M | $0 | $0 |
| Purchases of property and equipment | -$18.5M | -$22.0M | -$33.3M |
| Other | -$3.5M | $6.8M | $807.0K |
| Net cash used in investing activities | -$18.3M | -$35.4M | -$48.2M |
| Borrowings on credit agreement | $0 | $235.5M | $470.0M |
| Payments on credit agreement | $0 | -$235.5M | -$474.0M |
| Payments on term loan | -$18.8M | -$12.5M | -$12.5M |
| Payments of contingent consideration liabilities | -$3.2M | -$1.2M | -$1.8M |
| Payments on finance lease obligations | -$2.0M | -$2.9M | -$2.6M |
| Proceeds from issuance of common stock | $3.2M | $3.6M | $4.9M |
| Repurchases of common stock | -$86.7M | -$1.7M | -$919.0K |
| Other | -$63.0K | $135.0K | -$8.8M |
| Net cash used in financing activities | -$107.5M | -$14.5M | -$25.7M |
| Net increase in cash and cash equivalents | $145.3M | $156.7M | $63.4M |
| Cash paid for interest | $34.4M | $40.0M | $42.3M |
| Equipment financed through finance leases | $0 | $0 | $132.0K |
| Property and equipment included in accounts payable | $1.5M | $1.4M | $2.9M |
No quarter-by-quarter statement was filed.
Corporate structure
Pediatrix Medical Group sits at the top of its group. 3 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Pediatrix Medical Group
- VANGUARD CAPITAL MANAGEMENT LLC Filed SCHEDULE 13G on Pediatrix Medical Group, latest Sep 3, 2026 (2 filings since Apr 30, 2026)
- VANGUARD GROUP INC Filed SCHEDULE 13G/A on Pediatrix Medical Group, latest Sep 3, 2026 (5 filings since Feb 10, 2022)
- VANGUARD PORTFOLIO MANAGEMENT LLC Filed SCHEDULE 13G on Pediatrix Medical Group, latest Sep 3, 2026 (2 filings since Apr 29, 2026)
- DIMENSIONAL FUND ADVISORS LP Filed SCHEDULE 13G on Pediatrix Medical Group, latest Jul 14, 2026 (3 filings since Feb 9, 2024)
- BlackRock Filed SCHEDULE 13G/A on Pediatrix Medical Group, latest Jul 17, 2025 (5 filings since Jan 26, 2022)
- AllianceBernstein Filed SCHEDULE 13G/A on Pediatrix Medical Group, latest Jun 3, 2025 (6 filings since Feb 14, 2022)
- Rubric Capital Management LP Filed SCHEDULE 13G/A on Pediatrix Medical Group, latest Feb 13, 2025 (2 filings since Nov 13, 2024)
- EARNEST PARTNERS LLC Filed SC 13G/A on Pediatrix Medical Group, latest Jun 10, 2024 (4 filings since Feb 11, 2022)
- LAZARD ASSET MANAGEMENT LLC Filed SC 13G/A on Pediatrix Medical Group, latest Feb 15, 2024 (4 filings since Mar 8, 2023)
- FMR LLC Filed SC 13G/A on Pediatrix Medical Group, latest Feb 9, 2023 (2 filings since Feb 9, 2022)
- Starboard Value LP Filed SC 13D/A on Pediatrix Medical Group, latest Jan 20, 2023 (2 filings since Dec 2, 2022)
- ArrowMark Colorado Holdings LLC Filed SC 13G/A on Pediatrix Medical Group, latest Feb 14, 2022
- Pediatrix Medical Group Sunrise
- Pediatrix Management Services, Inc. Subsidiary · Florida, United States
- PMG Services, Inc. (d/b/a Pediatrix Services, Inc.) Subsidiary · Florida, United States
Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Pediatrix Medical Group reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Land | $2.0M7 Dec 31, 2025 | $2.0M7 Dec 31, 2024 | 0% |
| Buildings and improvements | $8.3M7 Dec 31, 2025 | $8.3M7 Dec 31, 2024 | 0% |
| Property and equipment, before depreciation | $171.5M7 Dec 31, 2025 | $165.7M7 Dec 31, 2024 | +3.5% |
| Accumulated depreciation | $132.3M7 Dec 31, 2025 | $126.5M7 Dec 31, 2024 | +4.6% |
| Property and equipment, net | $39.2M7 Dec 31, 2025 | $39.2M7 Dec 31, 2024 | 0% |
| Operating-lease assets (leased space) | $31.1M7 Dec 31, 2025 | $34.1M7 Dec 31, 2024 | −8.7% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $375.2M7 Dec 31, 2025 | $229.9M7 Dec 31, 2024 | +63.2% |
| Marketable securities, current | $124.5M7 Dec 31, 2025 | $118.6M7 Dec 31, 2024 | +5.0% |
| Debt securities available for sale | $124.5M7 Dec 31, 2025 | $118.6M7 Dec 31, 2024 | +5.0% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Goodwill | $1.3B7 Dec 31, 2025 | $1.2B7 Dec 31, 2024 | +1.5% |
| Finite-lived intangibles, gross | $74.7M7 Dec 31, 2025 | $75.8M7 Dec 31, 2024 | −1.4% |
| Accumulated amortization | $57.8M7 Dec 31, 2025 | $64.2M7 Dec 31, 2024 | −9.9% |
| Finite-lived intangibles, net | $16.9M7 Dec 31, 2025 | $11.6M7 Dec 31, 2024 | +45.4% |
Properties, in its own words
Our corporate office building, which we own, is located in Sunrise, Florida and contains 80,000 square feet of office space. We also lease space in medical office buildings affiliated with hospitals and other facilities for our business and medical offices, and other needs. We believe that our facilities and the equipment used in our business are in good condition, in all material respects, and sufficient for our present needs.
Item 2 of the 10-K filed Feb 19, 2026.6
Leadership
Who has led Pediatrix Medical Group, and when. Pick a name to see everywhere that person has worked.
Chief financial officer
Chief operating officer
19801990200020102020
- Chief executive officerJames D. Swift Mar 3, 2023 to Sep 3, 202415
- Chief executive officerMark S. Ordan Jul 14, 2020 to Mar 3, 202316
- Chief executive officerRoger Medel Md. Jan 5, 2006 to Jun 3, 202017
- PresidentKarl B. Wagner Jun 3, 2016 to Jun 8, 201618
- PresidentMichael D. Stanley Feb 16, 2012 to Jun 3, 201619
- PresidentJoseph M. Calabro Jun 6, 2006 to Jun 4, 201920
- Chief financial officerKasandra H. Rossi Oct 4, 2024 to now21
- Chief financial officerC. Marc Richards Oct 2, 2020 to Aug 13, 202422
- Chief financial officerStephen D. Farber Nov 9, 2018 to Oct 2, 202023
- Chief financial officerVivian Lopez-Blanco Jan 4, 2010 to Jun 13, 201824
- Chief financial officerKarl B. Wagner Feb 10, 2006 to Sep 4, 200925
- Chief operating officerCurtis Pickert Feb 22, 2023 to Jun 4, 202426
- Chief operating officerJames D. Swift Nov 9, 2022 to Nov 9, 202227
- Chief operating officerWilliam C. Hawk Jul 10, 2013 to Jan 30, 201528
- Chief operating officerJoseph M. Calabro Feb 10, 2006 to Jun 1, 201829
Board members and other officers (36)
- EVP, GC & Corp SecDavid Haddock Jun 24, 2026 to now30
- EVP, Chief Invest & StrategyDon Gregory Neeb Aug 5, 2025 to now31
- EVP, Natl & Market OperationsLee Wood Feb 22, 2023 to Jun 4, 202432
- EVP Chief ERM/Legal Ops OffMary Ann E. Moore Nov 23, 2021 to now33
- EVP Chf Strategy & Growth OffiNicholas Nikolopoulos Feb 19, 2020 to Sep 17, 202034
- Pres., PDX & OBX Medical GroupRoger Mack Hinson Sep 29, 2020 to Mar 3, 202235
- Principal Accounting OfficerJohn C. Pepia Aug 12, 2016 to Nov 10, 202136
- Pres., Pediatrix Medical GroupMichael D. Stanley Jun 4, 2013 to Jun 3, 201537
- Sr.VP,General Counsel & Secy.Dominic J. Andreano May 10, 2012 to Sep 28, 202238
- Pres, American AnesthesiologyKarl B. Wagner Jun 3, 2010 to Jun 10, 201539
- SVP, GEN. COUNSEL & SECRETARYThomas W. Hawkins Feb 13, 2006 to Jun 3, 200840
- Board memberKurt Douglas Newman Jul 1, 2025 to now41
- Board memberSylvia Jean Young May 15, 2023 to now42
- Board memberJames D. Swift Jun 16, 2023 to Sep 3, 202443
- Board memberLaura McDuffie May 13, 2022 to now44
- Board memberGuy P. Sansone Jul 14, 2020 to now45
- Board memberMark S. Ordan Jul 14, 2020 to now16
- Board memberShirley A. Weis Jul 14, 2020 to now46
- Board memberThomas McEachin Jul 14, 2020 to now47
- Board memberJohn M. Starcher Jr. Jul 15, 2020 to now48
- Board memberCarlos A. Migoya May 22, 2019 to Feb 18, 202049
- Board memberMichael A. Rucker May 22, 2019 to now50
- Board memberKarey D. Barker May 8, 2015 to May 14, 202151
- Board memberDonna E. Shalala May 7, 2010 to Mar 2, 201852
- Board memberCesar L. Alvarez May 7, 2009 to Feb 18, 202053
- Board memberDany Garcia Nov 6, 2008 to May 5, 201154
- Board memberManuel Kadre May 10, 2007 to May 14, 202155
- Board memberRoger Medel Md. Jan 5, 2006 to May 13, 202217
- Board memberPascal J. Goldschmidt Mar 17, 2006 to Feb 18, 202056
- Board memberLawrence Mullen May 5, 2006 to May 5, 200657
- Board memberPaul G. Gabos May 5, 2006 to May 14, 202158
- Board memberRoger K. Freeman May 5, 2006 to Jun 3, 201459
- Board memberWaldemar A. Carlo May 5, 2006 to May 14, 202160
- Board memberEnrique Sosa May 8, 2006 to Feb 18, 202061
- General counselMary Ann E. Moore Mar 3, 2023 to Jun 4, 202462
- General counselThomas W. Hawkins Jun 6, 2006 to Feb 22, 201263
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- PMG Services, Inc. (d/b/a Pediatrix Services, Inc.) Florida5
- Pediatrix Management Services, Inc. Florida5
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Former names
Timeline
- Aug 4, 20268-K Results of operations64
- Jul 24, 20268-K Executive or director change; Regulation FD disclosure65
- Jul 15, 20268-K Results of operations; Regulation FD disclosure66
- May 7, 20268-K Executive or director change; Shareholder vote67
- May 5, 20268-K Results of operations68
- Feb 19, 20268-K Results of operations69
- Nov 3, 20258-K Results of operations70
- Aug 18, 20258-K Regulation FD disclosure; Other events71
- Aug 5, 20258-K Results of operations72
- Jul 1, 20258-K Executive or director change; Regulation FD disclosure73
- May 8, 20258-K Shareholder vote74
- May 6, 20258-K Results of operations75
- Mar 3, 2023New chief executive James D. Swift becomes CEO15
- Jul 14, 2020New chief executive Mark S. Ordan becomes CEO16
- Jan 5, 2006New chief executive Roger Medel Md. becomes CEO17
- 1979Founded Founded1
Calendar
Coming up
- Nov 2, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported $0.64 a share, on Nov 3, 2025.76
When it reported results
- Aug 4, 2026Reported quarterly or annual results64
- Jul 15, 2026Reported quarterly or annual results66
- May 5, 2026Reported quarterly or annual results68
- Feb 19, 2026Reported quarterly or annual results69
- Nov 3, 2025Reported quarterly or annual results70
- Aug 5, 2025Reported quarterly or annual results72
- May 6, 2025Reported quarterly or annual results75
- Feb 20, 2025Reported quarterly or annual results77
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
280 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 44 major events, 135 insider forms, 38 large holders, 43 other. The latest 20:
- Sep 14, 2026144 EDGAR
- Sep 14, 2026144 EDGAR
- Sep 14, 20264 EDGAR
- Sep 10, 2026144 EDGAR
- Sep 3, 2026SCHEDULE 13G EDGAR
- Sep 3, 2026SCHEDULE 13G EDGAR
- Sep 3, 2026SCHEDULE 13G/A EDGAR
- Aug 18, 20264 EDGAR
- Aug 14, 2026144 EDGAR
- Aug 14, 20264 EDGAR
- Aug 14, 20264 EDGAR
- Aug 14, 20264 EDGAR
- Aug 14, 20264 EDGAR
- Aug 14, 20264 EDGAR
- Aug 14, 20264 EDGAR
- Aug 14, 20264 EDGAR
- Aug 14, 20264 EDGAR
- Aug 4, 202610-Q EDGAR
- Aug 4, 20268-K EDGAR
- Jul 24, 20268-K EDGAR
The 280 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
32 open-market trades by officers, directors and large owners since October 2021: 0 buys and 32 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| May 13, 2026 | Weis Shirley ADirector | Sale | 36,028 | $23.75 | $855.7K | Form 4 |
| Dec 15, 2025 | ORDAN MARK SChief Executive Officer | Sale | 23,000 | $22.41 | $515.4K | Form 4 |
| Nov 17, 2025 | Rucker Michael A.Director | Sale | 10,478 | $23.00 | $241.0K | Form 4 |
| Nov 6, 2025 | Linynsky Laura ADirector | Sale | 10,000 | $21.65 | $216.5K | Form 4 |
| Nov 13, 2024 | ORDAN MARK SChief Executive Officer | Sale | 27,600 | $15.35 | $423.7K | Form 4 |
| Nov 8, 2024 | Moore Mary Ann EEVP, GC, Chief Admin Off & Sec | Sale | 8,108 | $16.00 | $129.7K | Form 4 |
| Aug 30, 2024 | Swift James DChief Executive Officer | Sale | 11,100 | $10.79 | $119.8K | Form 4 |
| Aug 27, 2024 | Linynsky Laura ADirector | Sale | 7,000 | $11.16 | $78.1K | Form 4 |
| Aug 12, 2024 | Richards C MarcEVP, Chief Financial Officer | Sale | 17,438 | $10.08 | $175.8K | Form 4 |
| Aug 9, 2024 | Richards C MarcEVP, Chief Financial Officer | Sale | 32,562 | $10.08 | $328.2K | Form 4 |
| Dec 14, 2023 | Moore Mary Ann EEVP, GC, Chief Admin Off & Sec | Sale | 2,120 | $9.62 | $20.4K | Form 4 |
| Dec 14, 2023 | Swift James DChief Executive Officer | Sale | 5,764 | $9.58 | $55.2K | Form 4 |
| Jun 14, 2023 | Swift James DChief Executive Officer | Sale | 13,193 | $14.14 | $186.5K | Form 4 |
| May 25, 2023 | ORDAN MARK SChief Executive Officer | Sale | 33,000 | $13.26 | $437.6K | Form 4 |
| May 19, 2023 | Weis Shirley ADirector | Sale | 1,007 | $13.63 | $13.7K | Form 4 |
| May 18, 2023 | Weis Shirley ADirector | Sale | 17,993 | $13.55 | $243.8K | Form 4 |
| Nov 21, 2022 | ORDAN MARK SChief Executive Officer | Sale | 22,166 | $15.45 | $342.5K | Form 4 |
| Nov 7, 2022 | Swift James DChief Executive Officer | Sale | 24,000 | $15.31 | $367.4K | Form 4 |
| Jan 11, 2022 | MEDEL ROGER MDDirector | Sale | 40,107 | $26.58 | $1.1M | Form 4 |
| Jan 10, 2022 | MEDEL ROGER MDDirector | Sale | 59,893 | $26.44 | $1.6M | Form 4 |
All 32 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- VANGUARD CAPITAL MANAGEMENT LLCSCHEDULE 13G, 2 filings Apr 30, 2026 to Sep 3, 202678
- VANGUARD GROUP INCSCHEDULE 13G/A, 5 filings Feb 10, 2022 to Sep 3, 202679
- VANGUARD PORTFOLIO MANAGEMENT LLCSCHEDULE 13G, 2 filings Apr 29, 2026 to Sep 3, 202680
- DIMENSIONAL FUND ADVISORS LPSCHEDULE 13G, 3 filings Feb 9, 2024 to Jul 14, 202681
- BlackRockSCHEDULE 13G/A, 5 filings Jan 26, 2022 to Jul 17, 202582
- AllianceBernsteinSCHEDULE 13G/A, 6 filings Feb 14, 2022 to Jun 3, 202583
- Rubric Capital Management LPSCHEDULE 13G/A, 2 filings Nov 13, 2024 to Feb 13, 202584
- EARNEST PARTNERS LLCSC 13G/A, 4 filings Feb 11, 2022 to Jun 10, 202485
- LAZARD ASSET MANAGEMENT LLCSC 13G/A, 4 filings Mar 8, 2023 to Feb 15, 202486
- FMR LLCSC 13G/A, 2 filings Feb 9, 2022 to Feb 9, 202387
- Starboard Value LPSC 13D/A, 2 filings Dec 2, 2022 to Jan 20, 202388
- ArrowMark Colorado Holdings LLCSC 13G/A, 1 filing Feb 14, 202289
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Mark S. Ordan | 67 | $970.0K | $14.1M90 |
| 2025 | Don Gregory Neeb | 58 | $229.2K | $5.3M90 |
| 2025 | Mary Ann E. Moore | 66 | $500.0K | $3.0M90 |
| 2025 | James D. SwiftM.D. | $54.2K | $2.8M90 | |
| 2025 | Kasandra H. Rossi | 53 | $437.5K | $1.9M90 |
| 2024 | Former ChiefExecutive Officer | $650.0K | $3.3M90 | |
| 2024 | Executive VicePresident, | $368.8K | $1.3M90 | |
| 2023 | Former ChiefExecutive Officer | $650.0K | $2.2M90 | |
| 2023 | General CounselChief Administrative Officer and Secretary | $475.0K | $1.8M90 |
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| BlackRock, Inc. | 13,714,275 | $347.4M | 0.0% | +139,902 |
| Vanguard Portfolio Management LLC | 5,985,147 | $151.6M | 0.0% | −168,979 |
| Dimensional Fund Advisors LP | 4,220,311 | $106.9M | 0.0% | +363,396 |
| Vanguard Capital Management LLC | 3,620,040 | $91.7M | 0.0% | −36,281 |
| State Street Corp | 3,533,248 | $89.5M | 0.0% | +154,748 |
| Victory Capital Management Inc | 3,416,913 | $86.6M | 0.0% | −425,020 |
| Wasatch Advisors LP | 2,498,884 | $63.3M | 0.4% | +448,360 |
| Geode Capital Management, LLC | 2,226,028 | $56.4M | 0.0% | +38,061 |
| American Century Companies Inc | 2,192,017 | $55.5M | 0.0% | −1,733,349 |
| Fuller & Thaler Asset Management, Inc. | 1,721,451 | $43.6M | 0.1% | +492,020 |
| Allspring Global Investments Holdings, LLC | 1,618,910 | $42.3M | 0.1% | +643,777 |
| D. E. Shaw & Co., Inc. | 1,613,100 | $40.9M | 0.0% | −95,333 |
| Rockefeller Capital Management L.P. | 1,338,592 | $33.9M | 0.1% | +576,095 |
| Morgan Stanley | 1,328,477 | $33.7M | 0.0% | +77,852 |
| Charles Schwab Investment Management Inc | 1,294,185 | $32.8M | 0.0% | −149,206 |
| Renaissance Technologies LLC | 1,287,300 | $32.6M | 0.0% | −245,000 |
| Invesco Ltd. | 1,173,609 | $29.7M | 0.0% | +251,432 |
| Public Sector Pension Investment Board | 987,860 | $25.0M | 0.1% | +566,451 |
| Northern Trust Corp | 934,307 | $23.7M | 0.0% | +34,037 |
| Royce & Associates LP | 914,348 | $23.2M | 0.2% | +235,578 |
| Silvercrest Asset Management Group LLC | 912,380 | $23.1M | 0.2% | −58,230 |
| Nuveen, LLC | 868,272 | $22.0M | 0.0% | −84,827 |
| Goldman Sachs Group Inc | 825,636 | $20.9M | 0.0% | −25,828 |
| Bridgeway Capital Management, LLC | 761,642 | $19.3M | 0.3% | +9,866 |
| Fmr LLC | 741,386 | $18.8M | 0.0% | −1,526,048 |
13F reports cover disclosed long positions in U.S. stocks only.
Members of Congress who traded it
1 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.
| Date | Member | Trade | Amount | Vs S&P since | Filing |
|---|---|---|---|---|---|
| Oct 15, 2019 | Donna Shalala, House | Sale | $50,001 - $100,000 | +133.4% | Report |
Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).
SEC filer profile
How Pediatrix Medical Group is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARPediatrix Medical Group, Inc.2
- CIK0000893949
- Employer ID (EIN)26-36675386
- Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company6
- Incorporated inFlorida6
- Fiscal year endsDecember 312
- Industry code (SIC)8060 Services-Hospitals2
- SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance2
- Business address1301 Concord Terrace, Sunrise, FL 333232
- Phone95438401752
- Shares outstanding81,253,271 as of Jul 31, 202613
- Public float$899.9M as of Jun 30, 20256
- AuditorPricewaterhouseCoopers LLP, Miami, Florida PCAOB ID 238; it also attests to the company’s internal control over financial reporting6
- On EDGAR sinceMay 10, 19962
- Filings1,473 in all: 4 (671), 8-K (231), SC 13G/A (98), 10-Q (92), SC 13G (36), 3 (34), DEF 14A (31), 10-K (28)2
All 55 form types
DEFA14A (25), 144 (23), UPLOAD (20), CORRESP (18), 4/A (17), S-8 (17), ARS (14), 11-K (12), NO ACT (12), SC 13D/A (11), S-8 POS (8), 3/A (6), 5 (6), 8-K/A (5), SCHEDULE 13G/A (5), 425 (4), D (4), SC 13D (4), 8-A12B (3), NT 10-Q (3), SCHEDULE 13G (3), 10-K/A (2), 10-K405 (2), CERTNYS (2), NT 11-K (2), S-1/A (2), SEC STAFF LETTER (2), 10-K405/A (1), 10-Q/A (1), 15-12B (1), 25-NSE (1), 424A (1), 424B3 (1), 424B4 (1), 8-A12B/A (1), 8-A12G (1), 8-A12G/A (1), 8-K12B (1), CT ORDER (1), DEFR14A (1), DFAN14A (1), NT 10-K (1), PRE 14A (1), S-1 (1), S-3ASR (1), S-4 (1), S-4/A (1)
- Latest filingsAnnual report (10-K) Feb 19, 2026
Quarterly report (10-Q) Aug 4, 2026
Proxy statement (DEF 14A) Mar 27, 2026
Latest 8-K (8-K) Aug 4, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, par value $.01 per share | MD | New York Stock Exchange |
From the cover page of the 10-K filed Feb 19, 2026 (Section 12(b) of the Exchange Act).6
Risk factors and legal proceedings
The risks Pediatrix Medical Group names in Item 1A of its 10-K filed Feb 19, 2026: 41 risks under these headings, as written.6
- Risks Related to Macroeconomic Conditions
- Economic conditions could have an adverse effect on our business.
- The birth rate in the United States has declined and may decline further.
- Unfavorable changes or conditions could occur in the states where our operations are concentrated.
- The value of our common stock may fluctuate.
- The widespread outbreak of an illness or any other communicable disease, or any other public health crisis, and the governmental responses thereto, could adversely affect our business, financial condition and results of operations.
- Risks Related to Governmental Changes and the Healthcare Regulatory Environment
- Potential healthcare reform efforts may have a significant effect on our business.
- COVID-19 necessitated the delivery of certain healthcare services remotely via telehealth, which is subject to extensive federal and state regulation, as well as temporary waivers tied to the COVID-19 public health emergency, and certain flexibilities afforded to the provision and reimbursement of telehealth have been and may continue to be rolled back.
- The Medicare Access and CHIP Reauthorization Act of 2015 (“MACRA”) and potential changes to it may have an adverse effect on our business.
- The Transparency in Coverage Final Rule, which requires certain health plans and issuers to publish pricing information on in-network and out-of-network providers and make price comparison and cost-sharing information available to insureds, could have a material impact on our business.
- State budgetary constraints and the uncertainty over the future of Medicaid could have an adverse effect on our reimbursement from Medicaid programs.
The other 31 risks
- Congress or states have, and may continue to, enact laws restricting the amount out-of-network providers of services can charge and recover for such services.
- Expanding eligibility of GHC Programs could adversely affect our reimbursement.
- Government-funded programs, private insurers or state laws and regulations may limit, reduce or make retroactive adjustments to reimbursement amounts or rates.
- We may become subject to billing investigations by federal and state government authorities and private insurers.
- The healthcare industry is highly regulated, and government authorities may determine that we have failed to comply with applicable laws, rules or regulations.
- Government authorities or other parties may assert that our business practices violate antitrust laws.
- Our affiliated physicians and other individual providers may not satisfy all conditions of payment or otherwise appropriately record or document services that they provide.
- State healthcare transaction laws could adversely affect our operations.
- Risks Related to Our Business Strategy
- During 2024, we undertook a transformation of our revenue cycle management function from an outsourced provider to a hybrid function that utilizes both our corporate personnel as well as third-party service providers. Our failure to execute a hybrid revenue cycle management function efficiently and effectively may have a material impact on our business, financial condition, results of operations, cash flows and the trading price of our securities.
- We currently outsource, and from time to time in the future may outsource, a portion of our internal business functions to third-party providers. Outsourcing these functions has significant risks, and our failure to successfully manage these risks could materially adversely affect our business, results of operations and financial condition.
- We may not find suitable acquisition candidates or successfully integrate our acquisitions. Our acquisitions may expose us to greater business risks and could affect our payor mix.
- We may not be able to successfully execute our same-unit and organic growth strategies.
- We may not effectively manage our growth.
- Hospitals or other customers may terminate their agreements with us, our physicians may lose the ability to provide services in hospitals or administrative fees paid to us by hospitals may be reduced.
- Risks Related to Operating our Business
- We are dependent upon our key management personnel for our future success and loss of our key management and other personnel or an inability to attract new management and other personnel could impact our business.
- Our quarterly results will likely fluctuate from period to period.
- We may write-off intangible assets, such as goodwill.
- We are subject to medical malpractice and other lawsuits that may not covered by insurance.
- The reserves that we have established related to our professional liability losses are subject to inherent uncertainties and if actual costs exceed our estimates this may lead to a reduction in our net earnings.
- We are subject to litigation risks.
- We may not be able to collect reimbursements for our services from third-party payors.
- Risks Related to our Capital Structure
- Our current indebtedness and any future indebtedness could adversely affect us by reducing our flexibility to respond to changing business and economic conditions and expose us to interest rate risk to the extent of any variable rate debt. In addition, a certain portion of our interest expense may not be deductible.
- Provisions of our articles and bylaws could deter takeover attempts, but our business could be negatively affected as a result of shareholder activism.
- Risks Related to Labor
- We may not be able to successfully recruit, onboard and retain qualified physicians and other clinicians and other personnel, and our compensation expense for existing clinicians and other personnel may increase.
- A significant number of our affiliated physicians or other clinicians could leave our affiliated physician practices or our affiliated physician practices may be unable to enforce the non-competition covenants of departed physicians.
- Information Systems, Cybersecurity and Data Privacy Risks
- We may not be able to maintain effective and efficient information systems or properly safeguard our information systems.
- We may experience difficulties implementing or enhancing technology, software and processes.
- Our use of artificial intelligence (“AI”) technologies may expose us to additional legal, regulatory, operational, and competitive risks.
- Hospitals could limit our ability to use our information management systems in our units by requiring us to use their own information management systems.
- Federal and state laws concerning the privacy and security of personal information may increase our costs and limit our ability to collect and use that information. Any failure or perceived failure by us to comply with such laws and regulations may harm our business and operations.
- Risks Related to Competition and Consolidation
- Our industry is highly competitive.
Legal proceedings
The information required by this Item is included in and incorporated herein by reference to Item 1. Business of this Form 10-K under “Government Investigations” and “Other Legal Proceedings.”
The opening of Item 3, Legal Proceedings.6
Links
- Websitewww.mednax.com1
- Websitewww.pediatrix.com1
- WikidataQ16981865
- SEC EDGARCIK 893949
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3Company websitePediatrix Medical Group logo
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18SEC EDGARKarl B. Wagner, President
- 19SEC EDGARMichael D. Stanley, President
- 20SEC EDGARJoseph M. Calabro, President
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30SEC EDGARDavid Haddock, EVP, GC & Corp Sec
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41SEC EDGARKurt Douglas Newman, Board member
- 42SEC EDGARSylvia Jean Young, Board member
- 43SEC EDGARJames D. Swift, Board member
- 44SEC EDGARLaura McDuffie, Board member
- 45SEC EDGARGuy P. Sansone, Board member
- 46SEC EDGARShirley A. Weis, Board member
- 47SEC EDGARThomas McEachin, Board member
- 48SEC EDGARJohn M. Starcher Jr., Board member
- 49SEC EDGARCarlos A. Migoya, Board member
- 50SEC EDGARMichael A. Rucker, Board member
- 51SEC EDGARKarey D. Barker, Board member
- 52SEC EDGARDonna E. Shalala, Board member
- 53SEC EDGARCesar L. Alvarez, Board member
- 54SEC EDGARDany Garcia, Board member
- 55SEC EDGARManuel Kadre, Board member
- 56SEC EDGARPascal J. Goldschmidt, Board member
- 57SEC EDGARLawrence Mullen, Board member
- 58SEC EDGARPaul G. Gabos, Board member
- 59SEC EDGARRoger K. Freeman, Board member
- 60SEC EDGARWaldemar A. Carlo, Board member
- 61SEC EDGAREnrique Sosa, Board member
- 62SEC EDGARMary Ann E. Moore, General counsel
- 63SEC EDGARThomas W. Hawkins, General counsel
- 64SEC EDGARResults of operations
- 65
- 66
- 67
- 68SEC EDGARResults of operations
- 69SEC EDGARResults of operations
- 70SEC EDGARResults of operations
- 71
- 72SEC EDGARResults of operations
- 73
- 74SEC EDGARShareholder vote
- 75SEC EDGARResults of operations
- 76NasdaqNasdaq calendar
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90